Taylor Hoffman Wealth Management lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 42.9% in the 3rd quarter, Holdings Channel.com reports. The fund owned 633 shares of the life sciences company’s stock after buying an additional 190 shares during the quarter. Taylor Hoffman Wealth Management’s holdings in Illumina were worth $193,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Baillie Gifford & Co. increased its position in shares of Illumina by 5.0% during the second quarter. Baillie Gifford & Co. now owns 16,775,175 shares of the life sciences company’s stock valued at $6,175,781,000 after acquiring an additional 799,884 shares in the last quarter. Jennison Associates LLC increased its position in shares of Illumina by 5.2% during the second quarter. Jennison Associates LLC now owns 5,976,219 shares of the life sciences company’s stock valued at $2,200,145,000 after acquiring an additional 296,541 shares in the last quarter. Edgewood Management LLC increased its position in shares of Illumina by 1.1% during the second quarter. Edgewood Management LLC now owns 4,157,827 shares of the life sciences company’s stock valued at $1,530,704,000 after acquiring an additional 46,899 shares in the last quarter. Nuveen Asset Management LLC increased its position in shares of Illumina by 67,829.8% during the second quarter. Nuveen Asset Management LLC now owns 2,260,705 shares of the life sciences company’s stock valued at $832,279,000 after acquiring an additional 2,257,377 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Illumina by 1.3% during the second quarter. Northern Trust Corp now owns 1,682,543 shares of the life sciences company’s stock valued at $619,428,000 after acquiring an additional 21,782 shares in the last quarter. 90.94% of the stock is owned by institutional investors.
In related news, SVP Charles Dadswell sold 1,220 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $279.88, for a total transaction of $341,453.60. Following the sale, the senior vice president now directly owns 5,386 shares of the company’s stock, valued at $1,507,433.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mostafa Ronaghi sold 4,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $310.93, for a total transaction of $1,243,720.00. Following the sale, the senior vice president now directly owns 80,585 shares in the company, valued at $25,056,294.05. The disclosure for this sale can be found here. Insiders have sold 32,638 shares of company stock worth $9,580,415 over the last three months. 0.38% of the stock is currently owned by insiders.
ILMN stock traded down $1.86 on Friday, hitting $293.39. The company had a trading volume of 935,600 shares, compared to its average volume of 1,040,401. The stock’s 50-day simple moving average is $302.08 and its 200 day simple moving average is $310.65. Illumina, Inc. has a 12-month low of $263.30 and a 12-month high of $380.76. The stock has a market cap of $44.23 billion, a price-to-earnings ratio of 51.29, a P/E/G ratio of 2.22 and a beta of 1.03. The company has a current ratio of 6.82, a quick ratio of 6.15 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 24th. The life sciences company reported $1.93 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.53. Illumina had a net margin of 28.14% and a return on equity of 22.05%. The firm had revenue of $907.00 million for the quarter, compared to the consensus estimate of $872.65 million. During the same period in the prior year, the firm posted $1.52 earnings per share. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. Research analysts forecast that Illumina, Inc. will post 6.44 earnings per share for the current year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Read More: How to trade on quiet period expirations
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.